Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Jiangsu ChengXing Phosph-Chemicals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Jiangsu ChengXing Phosph-Chemicals has a total shareholder equity of CN¥2.3B and total debt of CN¥1.7B, which brings its debt-to-equity ratio to 74.9%. Its total assets and total liabilities are CN¥5.3B and CN¥3.0B respectively. Jiangsu ChengXing Phosph-Chemicals's EBIT is CN¥103.9M making its interest coverage ratio 5. It has cash and short-term investments of CN¥506.3M.

Anahtar bilgiler

74.9%

Borç/özkaynak oranı

CN¥1.70b

Borç

Faiz karşılama oranı	5x
Nakit	CN¥506.29m
Eşitlik	CN¥2.28b
Toplam yükümlülükler	CN¥3.03b
Toplam varlıklar	CN¥5.30b

Son finansal sağlık güncellemeleri

Here's Why Jiangsu ChengXing Phosph-Chemicals (SHSE:600078) Has A Meaningful Debt Burden

Sep 30

Is Jiangsu ChengXing Phosph-Chemicals (SHSE:600078) A Risky Investment?

Jun 07

Recent updates

Here's Why Jiangsu ChengXing Phosph-Chemicals (SHSE:600078) Has A Meaningful Debt Burden

Sep 30

We Think That There Are Some Issues For Jiangsu ChengXing Phosph-Chemicals (SHSE:600078) Beyond Its Promising Earnings

Sep 06

Jiangsu ChengXing Phosph-Chemicals Co., Ltd.'s (SHSE:600078) Prospects Need A Boost To Lift Shares

Aug 26

Is Jiangsu ChengXing Phosph-Chemicals (SHSE:600078) A Risky Investment?

Jun 07

Jiangsu ChengXing Phosph-Chemicals Co., Ltd.'s (SHSE:600078) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Apr 04

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 600078's short term assets (CN¥2.0B) exceed its short term liabilities (CN¥1.5B).

Uzun Vadeli Yükümlülükler: 600078's short term assets (CN¥2.0B) exceed its long term liabilities (CN¥1.6B).

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 600078's net debt to equity ratio (52.6%) is considered high.

Borcun Azaltılması: 600078's debt to equity ratio has reduced from 157.5% to 74.9% over the past 5 years.

Borç Kapsamı: 600078's debt is well covered by operating cash flow (22.4%).

Faiz Kapsamı: 600078's interest payments on its debt are well covered by EBIT (5x coverage).

Jiangsu ChengXing Phosph-Chemicals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why Jiangsu ChengXing Phosph-Chemicals (SHSE:600078) Has A Meaningful Debt Burden

Is Jiangsu ChengXing Phosph-Chemicals (SHSE:600078) A Risky Investment?

Recent updates

Jiangsu ChengXing Phosph-Chemicals Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Here's Why Jiangsu ChengXing Phosph-Chemicals (SHSE:600078) Has A Meaningful Debt Burden

We Think That There Are Some Issues For Jiangsu ChengXing Phosph-Chemicals (SHSE:600078) Beyond Its Promising Earnings

Second quarter 2024 earnings released: CN¥0.014 loss per share (vs CN¥0.20 loss in 2Q 2023)

Jiangsu ChengXing Phosph-Chemicals Co., Ltd.'s (SHSE:600078) Prospects Need A Boost To Lift Shares

Jiangsu ChengXing Phosph-Chemicals Co., Ltd. to Report First Half, 2024 Results on Aug 31, 2024

Is Jiangsu ChengXing Phosph-Chemicals (SHSE:600078) A Risky Investment?

First quarter 2024 earnings released: CN¥0.011 loss per share (vs CN¥0.03 profit in 1Q 2023)

Full year 2023 earnings released: CN¥0.092 loss per share (vs CN¥0.79 profit in FY 2022)

Jiangsu ChengXing Phosph-Chemicals Co., Ltd., Annual General Meeting, May 17, 2024

Jiangsu ChengXing Phosph-Chemicals Co., Ltd.'s (SHSE:600078) Share Price Boosted 28% But Its Business Prospects Need A Lift Too

Jiangsu ChengXing Phosph-Chemicals Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

Now 21% undervalued

Jiangsu ChengXing Phosph-Chemicals Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: EPS: CN¥0.002 (vs CN¥0.057 loss in 3Q 2022)

Now 20% undervalued after recent price drop

Second quarter 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.81 profit in 2Q 2022)

Jiangsu ChengXing Phosph-Chemicals Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Investor sentiment deteriorates as stock falls 17%

Full year 2022 earnings released: EPS: CN¥0.79 (vs CN¥3.04 in FY 2021)

Less than half of directors are independent

Insufficient new directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: CN¥0.13 loss per share (vs CN¥0.14 profit in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.81 (vs CN¥0.011 loss in 2Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

First quarter 2022 earnings released: EPS: CN¥0.10 (vs CN¥0.006 in 1Q 2021)

Insufficient new directors

Now 20% undervalued after recent price drop

Now 24% undervalued after recent price drop

Now 23% undervalued

Second quarter 2021 earnings released: CN¥2.45 loss per share (vs CN¥0.005 loss in 2Q 2020)

Full year 2020 earnings released: CN¥3.34 loss per share (vs CN¥0.09 profit in FY 2019)

New 90-day low: CN¥3.24

New 90-day low: CN¥3.45

New 90-day low: CN¥4.11

Third quarter earnings released

New 90-day low: CN¥4.23

Jiangsu ChengXing Phosph-Chemicals Co., Ltd. to Report Q3, 2020 Results on Oct 31, 2020

New 90-day low: CN¥4.32

First half earnings released

New 90-day high - CN¥5.29

Jiangsu ChengXing Phosph-Chemicals Co., Ltd. to Report First Half, 2020 Results on Aug 29, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin